Current Report Filing (8-k)
June 28 2019 - 1:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
June 25, 2019
MARIMED
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
0-54433
|
|
27-4672745
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
10
Oceana Way, Norwood, Massachusetts
|
|
02062
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(617) 795-5140
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act: None.
Title
of each class
|
|
Ticker
symbol(s)
|
|
Name
of each exchange on which registered
|
Not
Applicable.
|
|
Not
Applicable.
|
|
Not
Applicable.
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02.
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
Effective
June 25, 2019, David Allen was appointed to the Board of Directors (the “Board”) of MariMed Inc. (the “Company”).
As a Director, he will serve as chairman of the Company’s Audit Committee. Mr. Allen’s appointment fills the vacancy
on the Board that resulted from the resignation of Thomas Kidrin on June 5, 2019. Mr. Allen has not had any direct or indirect
interest in any transactions with the Company that requires disclosure under Item 404(a) of Regulation S-K.
There
is no existing family relationship between Mr. Allen and any director or executive officer of the Company.
BIOGRAPHICAL
INFORMATION REGARDING THE INCOMING DIRECTOR
The
principal occupation and brief summary of Mr. Allen’s background is as follows:
David
Allen
, age 64, brings over 22 years of experience as a Director, CEO, and CFO of public companies. Presently, he serves as
Chief Financial Officer of True Drinks Holdings, Inc. From September 2018 to May 2019, Mr. Allen served as Chief Financial Officer
of Iconic Brands, Inc. Prior to that, from December 2014 to January 2018, Mr. Allen served as the Chief Financial Officer of WPCS
International, Inc. From 2007 to 2013, Mr. Allen served as the Chief Financial Officer and Executive Vice President of Administration
at Converted Organics, Inc., after serving as audit committee chair on the board of Converted Organics. Mr. Allen is currently
an Assistant Professor of Accounting at Southern Connecticut State University (“SCSU”), a position he has held since
2017. For the 12 years prior, he was an Adjunct Professor of Accounting at SCSU and Western Connecticut State University. Mr.
Allen is a licensed CPA and holds a bachelor’s degree in Accounting and a master’s degree in Taxation from Bentley
College. Mr. Allen’s background will allow him to make valuable contributions to the Board.
On
June 25, 2019, the Company announced the appointment of Mr. Allen to its Board. A copy of the press release is attached as Exhibit
99.1 hereto.
Item
9.01.
|
Financial
Statements and Exhibits.
|
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
MARIMED
INC.
|
|
|
|
Dated:
June 28, 2019
|
|
|
|
By:
|
/s/
ROBERT FIREMAN
|
|
|
Robert
Fireman, CEO
|
EXHIBIT
INDEX
MariMed (QX) (USOTC:MRMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MariMed (QX) (USOTC:MRMD)
Historical Stock Chart
From Sep 2023 to Sep 2024